Cancer Clinical Trial
Official title:
A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor in Subjects With Advanced Malignancies
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with a PD-1 inhibitor in subjects with advanced solid tumors.
This Phase 1-2 study is designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805, a fully human IgG1 antibody that binds specifically to CD163, in subjects with advanced solid tumors. The study consists of four parts: - Part A: a dose-escalation phase to determine the maximum-tolerated dose (MTD) or maximum achievable dose and the recommended phase 2 dose (RP2D) of OR2805 in a maximum of approximately 20 subjects. - Part B: a monotherapy expansion phase of up to approximately 40 subjects in each of 4 select tumor types at the RP2D to determine preliminary anti-tumor activity and further characterize safety. - Part C: a mini-dose-escalation at 2 doses of OR2805 in combination with a PD-1 inhibitor followed by a combination expansion cohort of up to approximately 40 subjects in each of 2 tumor types to determine the safety and preliminary anti-tumor activity of OR2805 in combination with a PD-1 inhibitor. - Part D: a biology cohort of up to approximately 20 subjects at the RP2D to determine mechanism of action and potential predictors of response and pharmacodynamics in subjects not eligible for either Part B or C. ;
NCT number | NCT05094804 |
Study type | Interventional |
Source | OncoResponse, Inc. |
Contact | Kate Harrop |
Phone | 425-420-0749 |
[email protected] | |
Status | Recruiting |
Phase | Phase 1/Phase 2 |
Start date | September 9, 2021 |
Completion date | August 15, 2024 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Enrolling by invitation |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT04444544 -
Quality of Life and High-Risk Abdominal Cancer Surgery
|
||
Completed |
NCT04281953 -
Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
|
||
Recruiting |
NCT02478931 -
Study of Personalized Cancer Therapy to Determine Response and Toxicity
|
||
Recruiting |
NCT04087252 -
An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment
|
Phase 1 |